Delcath Q2 revenue jumps 210% to $24.2M; net income $2.7M vs loss; FY25 guidance raised

DELCATH SYSTEMS, INC.

2025-Q2 EPS reported $0.09 vs consensus $0.03 ▲ beat (+252.9%)

Total revenue $24.2M (+210% YoY); HEPZATO KIT revenue $22.5M, CHEMOSAT $1.7M.
Net income $2.7M vs net loss $13.7M; Non-GAAP adj. EBITDA $9.8M vs loss $0.8M.
FY2025 revenue guidance raised to $93-96M; gross margins 83-85%; positive EBITDA and cashflow each quarter.
Cash and investments $81.0M, no debt; activated 3 new U.S. centers (20 total, 10 accepting referrals).
Received EU/UK authorization for clinical study of HEPZATO in metastatic colorectal cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.